At the request of US President Joe Biden, the US Department of Health and Human Services (HHS) and Department of Defense (DoD) yesterday said they have purchased an additional 100 million doses of COVID-19 vaccines from both Pfizer (NYSE: PFE) and Moderna (Nasdaq: MRNA) to help meet demand for COVID-19 vaccines in the USA.
The orders placed yesterday bring the vaccine purchased by the US government from these two companies to a total of 600 million doses, enough to vaccinate 300 million people. Each company is delivering 300 million doses in regular increments through the end of July 2021. Each company will leverage U.S.-based manufacturing capacity to fill, finish and ship vials as the bulk material is produced.”
“As the President directed, we are expanding our supply of COVID vaccines to protect people as quickly as possible,” said Acting HHS Secretary Norris Cochran, adding: “These purchases will allow us to accelerate our vaccination efforts to get shots into the arms of the American people. While we rapidly ramp up the pace of vaccinations, I encourage everyone to take actions now to protect themselves and their families: wear a mask, wash your hands often, and practice physical distancing.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze